Media & Resources

NEW YORK – OCTOBER 27, 2021 – IAVI announced today the award of up to US$126 million from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates. This award supports preclinical activities and includes options for…

Biofabri and IAVI announce their intention to partner on efficacy trials of the tuberculosis vaccine candidate MTBVAC TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19. COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.…

Global consortium of expert partners will generate proof-of-concept data to support product licensure and future access.

The experimental vaccine primed the immune system as the first stage in the production of broadly neutralizing antibodies.

Research will continue on COVID-19 vaccine platform.

A study of MTBVAC efficacy in a macaque model of tuberculosis shows that the vaccine candidate protects against aerosol infection with Mycobacterium tuberculosis. Researchers from Europe and the U.S. demonstrate that the MTBVAC vaccine protects better than the current BCG vaccine in a model of tuberculosis in macaques and compare the immunological patterns to those…

Universally accessible HIV Prevention Technologies for African girls and young women through Knowledge applied from behavioral Economics (UPTAKE) presents a unique multidisciplinary collaboration of five leading research institutions in both Africa and Europe.

Aim is production of precursors to broadly neutralizing antibodies.